Global Human Recombinant Insulin Market: Key Developments
On April 26, 2022, Biologics Limited (BBL), a subsidiary of Biocon Ltd., announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at US$ 90 million, for company's recombinant human insulin brand Insugen by the Ministry of Health (MoH), Malaysia.
}Human Recombinant Insulin Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients